文献速递膀胱癌与上尿路尿路上皮癌

阿替利珠单抗对比化疗用于铂类治疗后的局部晚期或转移性尿路上皮癌:3期IMvigor211长期总生存与安全性更新

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
PubMed 文献 · Eur Urol · 2021-04-23

IMvigor211研究长期随访更新显示,在铂类治疗后的转移性尿路上皮癌意向治疗人群中,阿替利珠单抗组24个月总生存率为23%,化疗组为13%;安全性方面化疗组3/4级治疗相关不良事件(43% vs 22%)和导致停药的不良事件(18% vs 9%)更多,阿替利珠单抗组特别关注不良事件更多(35% vs 20%)但多为1-2级。

要点

  • 阿替利珠单抗组24个月OS率23%,化疗组13%
  • 化疗组3/4级治疗相关AE 43% vs 阿替利珠单抗22%
  • 阿替利珠单抗特别关注AE更多(35% vs 20%),多为1-2级

核心结论

  • 长期随访显示阿替利珠单抗在铂类治疗后mUC患者中具有持久的缓解,支持其在该人群中的使用,无论PD-L1状态如何。

研究设计与样本

  • 3期IMvigor211临床试验的长期随访更新,分析意向治疗(ITT)人群的总生存(OS)和安全性。
  • 患者为铂类化疗期间或之后进展的mUC,按1:1随机接受阿替利珠单抗1200 mg或化疗(长春氟宁320 mg/m2、紫杉醇175 mg/m2或紫杉醇75 mg/m2,由研究者选择),每3周静脉给药。

主要发现

  • 中位随访33个月时,阿替利珠单抗组24个月OS率为23%,化疗组为13%。
  • 化疗组3/4级治疗相关不良事件发生率为43%,阿替利珠单抗组为22%。
  • 化疗组导致治疗中断的不良事件发生率为18%,阿替利珠单抗组为9%。
  • 阿替利珠单抗组特别关注不良事件发生率为35%,化疗组为20%,前者多为1-2级。

关键数值与推荐

  • 阿替利珠单抗推荐用于铂类化疗后的局部晚期或转移性尿路上皮癌,无论PD-L1状态。
  • 阿替利珠单抗剂量为1200 mg静脉给药每3周一次。
  • 化疗方案可选长春氟宁320 mg/m2、紫杉醇175 mg/m2或紫杉醇75 mg/m2。

临床怎么用

  • 对于铂类治疗后的mUC患者,可考虑使用阿替利珠单抗,无需依据PD-L1状态筛选。
  • 阿替利珠单抗的特别关注不良事件多为1-2级,需注意监测和管理。
  • 化疗的3/4级治疗相关不良事件和导致停药的不良事件发生率更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atezolizumab is an anti-PD-L1 immune checkpoint inhibitor recommended for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy, regardless of PD-L1 status, among other treatment settings. We conducted a long-term follow-up to the exploratory analysis of overall survival (OS) and safety for the IMvigor211 intent-to-treat (ITT) population. Patients with mUC and disease progression during or following platinum-based chemotherapy were randomised 1:1 to receive atezolizumab 1200 mg or chemotherapy (vinflunine 320 mg/m2, paclitaxel 175 mg/m2, or docetaxel 75 mg/m2 according to investigator choice) intravenously every 3 wk. Although the primary analysis did not demonstrate statistically significant longer OS for patients receiving atezolizumab versus chemotherapy, updated OS showed long-term durable remission. With a median of 33 mo of follow-up, the 24-mo OS rate was 23% with atezolizumab and 13% with chemotherapy. Safety findings were consistent with the primary analysis, with no new signals detected. Chemotherapy-treated patients experienced more grade 3/4 treatment-related adverse events (AEs; 43% vs 22%) and more AEs leading to treatment discontinuation (18% vs 9%). Atezolizumab-treated patients experienced more AEs of special interest (35% vs 20%), which tended to be grade 1-2. Our findings support the use of atezolizumab in platinum-treated patients with mUC regardless of PD-L1 status. PATIENT SUMMARY: We report follow-up results from a study of an immunotherapy treatment, atezolizumab, in patients with bladder cancer who had already received platinum-containing chemotherapy. This analysis compared the effectiveness of atezolizumab with chemotherapy over 2.5 years after starting treatment. The results show that patients who received atezolizumab lived longer and had manageable side effects compared with patients who received chemotherapy. This trial is registered at ClinicalTrials.gov as NCT02302807.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. van der Heijden MS, Loriot Y, Durán I, et al. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. Eur Urol. 2021. PMID: 33902955. doi:10.1016/j.eururo.2021.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。